User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

5979

Interactions with Platform & by Email *

INTERACTIONS

957

Unique # Participated *

PARTICIPANTS

179

Responses Validated *

VALIDATIONS

39

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Melanoma Incidence Surging at Significant Rate.....II-1
Current Standard Treatment for Melanoma.....II-1
High Unmet Need, and Challenges Abound.....II-1
1$100
   Recommencement of Discontinued Trials Provides a Ray a Hope!.....II-2
Cancer Vaccines: Potentially a Future Aid for Melanoma Treatment.....II-2
How Does Cancer Vaccines Works?.....II-2
1$100
   Whole Cell Vaccines for Melanoma.....II-3
Melanoma Therapeutics Market: Current & Future Analysis.....II-3
1$100
   Research for Novel Drug Therapies Rampant Worldwide.....II-4
Selected Products and Targets for Melanoma Treatment Under Phase III Clinical Trials
  (As of 2008).....II-4
1$100
   Selected Products and Targets for Melanoma Treatment Under Phase II Clinical Trials
  (As of 2008).....II-5
2$125
   Selected Products and Targets for Melanoma Treatment Under Phase I and Pre-Clinical
  Trials (As of 2008).....II-7
1$100
   Major Drugs Under Investigations for Metastatic Melanoma Treatment (As of
  2008).....II-8
What Does the Future Hold for Melanoma in Vaccines Space?.....II-8
Pipeline Analysis of Melanoma Vaccines.....II-8
Select Companies with Melanoma Vaccines under Phase III Clinical Trials.....II-8
1$100
   Select Companies with Melanoma Vaccines under Phase II Clinical Trials.....II-9
Select Companies with Melanoma Vaccines under Phase I Clinical Trials.....II-9
1$100
   What is Melanoma?.....II-10
Melanoma of Skin: A Grave form of Skin Cancer.....II-10
Melanoma Vis-à-vis Other Skin Cancers.....II-10
Types of Melanoma.....II-10
1$100
   Risk Factors for Melanoma.....II-11
Indoor Tanning Devices Hold Potential for Causing Skin Cancer.....II-11
Fair Skinned People: At Greater Risk.....II-11
1$100
   Prevention of Melanoma.....II-12
How Is Melanoma Detected?.....II-12
Ugly Duckling Sign – A New Approach for Melanoma Detection.....II-12
Diagnosis of Melanoma.....II-12
1$100
   Skin Biopsy, an Initial Step.....II-13
Fine Needle Aspirate (FNA).....II-13
Shave Biopsy.....II-13
Punch Biopsy.....II-13
Incisional Biopsy.....II-13
Excisional Biopsy.....II-13
Process After Biopsy: A Review.....II-13
1$100
   Analysis of Lymph Nodes Status, A Second Step.....II-14
Lactate Dehydrogenase Tests for Metastases Melanoma.....II-14
Prognosis of the Disease.....II-14
Melanoma Staging: Crucial for Treatment.....II-14
1$100
   Melanoma Treatment: An Overview.....II-15
Surgical Excision of Melanoma.....II-15
1$100
   Sentinel Lymph Node Biopsy.....II-16
Standard Treatment, Post Surgery.....II-16
Surgical Adjuvant Treatment.....II-16
1$100
   Standard Excision for Lentigo Maligna.....II-17
Surgical Treatment of Metastatic Melanoma.....II-17
Stereotactic Radiosurgery For Brain Metastases Melanoma.....II-17
Chemotherapy for Melanoma.....II-17
1$100
   Side Effects.....II-18
Chemotherapeutic Regional Perfusion.....II-18
Immunotherapy for Melanoma.....II-18
1$100
   Biochemotherapy: Chemo Plus Biotherapy.....II-19
Radiation Therapy.....II-19
Vaccine Immunotherapy.....II-19
Other Treatments.....II-19
1$100
   Vitamin D May Prevent Severe Melanoma Lesions.....II-20
Stress Accelerates Growth Of Melanoma Lesions.....II-20
Interaction Between Akt3 and (V600E)B-Raf Proteins in a Mole, Leads to
  Melanoma.....II-20
1$100
   Synta Obtains FDA Approval to Resume Development of Elesclomol.....II-21
Nexavar Fails in Late Stage Melanoma Trial.....II-21
Biovex Commences Phase III Clinical Trial of Oncovexgm-CSF.....II-21
Medarex and Bristol Myers Squibb Announces Enhanced Survival Rate through
  Ipilimumab.....II-21
1$100
   A Pain-Less Melanoma Test, Under Evaluation.....II-22
Encouraging Phase III Clinical Trials of a Melanoma Vaccine.....II-22
Plexxikon Announces Phase I Results of PLX4032".....II-22
1$100
   Provectus Treats Metastatic Melanoma Patients Under Phase II Clinical Study with
  PV-10.....II-23
GENOMEL Project Investigates Environmental/ Genetic Risk Factors for Melanoma.....II-23
Antigenics Announces Results of a Phase III Trial of Oncophage (vitespen)
  Vaccine.....II-23
1$100
   CuraGen Advances Phase II Clinical Trial of "CR011-vcMMAE".....II-24
Inovio Evaluates a Combination of Plasmid IL-12 and Electroporation Technology for the
  Treatment of Metastatic Melanoma.....II-24
2$125
   Pfizer Collaborates with Debiopharm.....II-26
PharmaSynth Licenses Muparfostat to Global TransBiotech.....II-26
Celldex Therapeutics Acquires CuraGen.....II-26
1$100
   Bristol-Myers Squibb Acquires Medarex.....II-27
Cephalon Acquires Outstanding Shares of Arana Therapeutics.....II-27
ImmunoVaccine Technologies Inks Agreement with Scancell.....II-27
1$100
   Vical Inks Agreement with Abic for Allovectin-7 Immunotherapeutic.....II-28
Immunomedics Collaborates with Alexis Biotech.....II-28
1$100
   NeoGenomics Signs Strategic Supply Deal with Abbott.....II-29
ErgoMed Collaborates with Genzyme.....II-29
PDS Biotechnology and Merck Eprova Sign CLA.....II-29
1$100
   FDA Oncologic Drug Advisory Committee Recommends for Approval, PEGINTRON® for Melanoma
  Treatment.....II-30
Takeda Acquires IDM Pharma.....II-30
Abraxis BioScience Receives FDA’s Orphan Drug Status for Abraxane.....II-30
Progen Pharmaceuticals Spins-Off its Manufacturing Business.....II-30
1$100
   Eli Lilly and Company Acquires SGX Pharmaceuticals.....II-31
GlaxoSmithKline and Synta Pharmaceutical Obtains the Orphan Drug Status from the US
  FDA, for Elesclomol.....II-31
Vical Inks Binding LOI with EIP.....II-31
GammaCan Signs Supply Deal with Bio Products Laboratory.....II-31
1$100
   Medarex and Bristol Myers Squibb Delays Submission of BLA, for Ipilimumab.....II-32
Pfizer Discontinues Phase 3 Clinical Trials of Tremelimumab, in Advanced Melanoma
  Patients.....II-32
Alnylam Pharmaceuticals Collaborates with University of California to Evaluate an RNAi
  Therapeutic for Metastatic Uveal Melanoma Treatment.....II-32
1$100
   GenVec and Cobra Ink Manufacturing Agreement.....II-33
SciClone Pharmaceuticals Sings a Deal with FDA for Thymalfasin.....II-33
Abraxis BioScience, NCCN, and AstraZeneca Collaborates For Assessment of Abraxane,
  the Anti-Cancer Drug.....II-33
1$100
   Oxford BioMedica Acquires Oxxon Therapeutics.....II-341$100
   Abraxis BioScience, Inc. (USA).....II-35
Astellas Pharma US, Inc. (USA).....II-35
Antigenics Inc. (USA).....II-35
1$100
   AVAX Technologies, Inc. (USA).....II-36
BioVex, Inc. (USA).....II-36
1$100
   GenVec, Inc. (USA).....II-37
GlaxoSmithKline Plc. (UK).....II-37
1$100
   Medarex Inc. (USA).....II-38
Merck KGAA (Germany).....II-38
Oxford Biomedica Plc. (UK).....II-38
1$100
   Pfizer, Inc. (USA).....II-39
Progen Pharmaceuticals Limited (Australia).....II-39
1$100
   Vical Inc. (USA).....II-401$100
   Table 1: World Recent Past, Current & Future Analysis for Melanoma Therapeutics Market by Geographic Region - US, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart).....II-411$350
   Table 2: World Historic Review for Melanoma Therapeutics Market by Geographic Region - US, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart).....II-421$350
   Table 3: World 13-Year Perspective for Melanoma Therapeutics Market by Geographic Region - Percentage Breakdown of Sales for the US, and Rest of World Markets for the Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-431$350
   A. Market Analysis.....III-1
Increasing Incidence of Melanoma Fuels Growth.....III-1
Table 4: Melanoma Incidence in the US by Gender: 2008 (includes corresponding Graph/Chart).....III-1

Table 5: Cancer Incidence in Males by Cancer Type: Percentage Share Breakdown in 2008 (includes corresponding Graph/Chart).....III-1
1$200
   Table 6: Cancer Incidence in Females by Cancer Type: Percentage Share Breakdown in 2008 (includes corresponding Graph/Chart).....III-2
Surging Mortality, Demands Novel Therapeutics for Melanoma.....III-2
Table 7: Melanoma Mortality in the US by Gender: 2005 & 2008 (includes corresponding Graph/Chart).....III-2
1$200
   Table 8: Five-Year Survival Rate for Patients with Melanoma of Skin in the US (1996-2003): Percentage Share Breakdown by Diagnosis Stage (includes corresponding Graph/Chart).....III-3
Fair-Skinned and Light Hair Whites at High RisK.....III-3
Table 9: Five-Year Survival Rate for Patients with Melanoma of Skin in the US (1996-2003): Percentage Share Breakdown by Race (includes corresponding Graph/Chart).....III-3
US Melanoma Fact Sheet: A Recapitulation.....III-3
1$200
   Major Players.....III-44$150
   Strategic Corporate Developments.....III-86$175
   B. Market Analytics.....III-14
Table 10: US Recent Past, Current & Future Analysis for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-14

Table 11: US Historic Review for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-14
1$200
   A. Market Analysis.....III-15
Select Regional Markets Under Review.....III-15
Australia.....III-15
World’s Leading Region with Highest Skin Cancer Incidence.....III-15
Table 12: Melanoma Incidence Rate in Australia by Age Group: 2008 (includes corresponding Graph/Chart).....III-15

Table 13: Melanoma Incidence Rate in Australian Males by Age Group: 2008 (includes corresponding Graph/Chart).....III-15
1$200
   Table 14: Melanoma Incidence Rate in Australian Females by Age Group: 2008 (includes corresponding Graph/Chart).....III-16
Other Key Facts on Melanoma Incidence in Australia.....III-16
The United Kingdom.....III-16
Young Women in UK Becoming Increasing Victims of Melanoma.....III-16
1$200
   Table 15: Newly Diagnosed Cases of Melanoma of Skin in the UK (2003-2005): Breakdown by Select Regions, and Gender (includes corresponding Graph/Chart).....III-17

Table 16: Mortality Due to Melanoma of Skin in the UK (2003-2005): Breakdown by Select Regions, and Gender (includes corresponding Graph/Chart).....III-17
1$200
   Major Players.....III-181$75
   Strategic Corporate Developments.....III-194$150
   B. Market Analytics.....III-23
Table 17: Rest of World Recent Past, Current & Future Analysis for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-23
1$200
   Table 18: Rest of World Historic Review for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-241$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com